PT - JOURNAL ARTICLE AU - Forshaw, Denise AU - Wall, Emma C AU - Prescott, Gordon AU - Dehbi, Hakim-Moulay AU - Green, Angela AU - Attree, Emily AU - Hismeh, Lyth AU - Strain, William D AU - Crooks, Michael G AU - Watkins, Caroline AU - Robson, Chris AU - Banerjee, Rajarshi AU - Lorgelly, Paula AU - Heightman, Melissa AU - Banerjee, Amitava AU - , TI - STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol AID - 10.1101/2022.07.21.22277893 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.21.22277893 4099 - http://medrxiv.org/content/early/2022/07/25/2022.07.21.22277893.short 4100 - http://medrxiv.org/content/early/2022/07/25/2022.07.21.22277893.full AB - Introduction Long COVID (LC), the persistent symptoms ≥12 weeks following acute COVID-19, presents major threats to individual and public health across countries, affecting over 1.5 million people in the UK alone. Evidence-based interventions are urgently required and an integrated care pathway (ICP) approach in pragmatic trials, which include investigations, treatments and rehabilitation for LC, could provide scalable and generalisable solutions at pace.Methods and analysis This is a pragmatic, multi-centre, cluster-randomised clinical trial of two components of an ICP (Coverscan™, a multi-organ MRI, and Living with COVID Recovery™, a digitally enabled rehabilitation platform) with a nested, Phase III, open label, platform randomised drug trial in individuals with LC. Cluster randomisation is at level of primary care networks so that ICP interventions are delivered as “standard of care” in that area. The drug trial randomisation is at individual level and initial arms are rivaroxaban, colchicine, famotidine/loratadine, compared with no drugs, with potential to add in further drug arms. The trial is being carried out in 6-10 NHS LC clinics in the UK and is evaluating the effectiveness of a pathway of care for adults with LC in reducing fatigue and other physical, psychological and functional outcomes (e.g. EQ-5D-5L, GAD-7, PHQ-9, WSAS, PDQ-5, CFQ, SF-12, MRC Dyspnoea score) at 3 months. The trial also includes an economic evaluation which will be described separately.Ethics and dissemination The protocol was reviewed by South Central - Berkshire Research Ethics Committee (reference: 21/SC/0416). All participating sites obtained local approvals prior to recruitment. Coverscan™ has UKCA certification (752965). The first participant was recruited in July 2022 and interim/final results will be disseminated in 2023, in a plan co-developed with public and patient representatives. The results will be presented at national and international conferences, published in peer reviewed medical journals, and shared via media (mainstream and social) and patient support organisations.Trial registration number ISRCTN10665760Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: WDS holds research grants from Bayer, Novo Nordisk and Novartis and has received speaker honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, Napp, Novartis, Novo Nordisk and Takeda, outside the submitted work. WDS is supported by the NIHR Exeter Clinical Research Facility and the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South West Peninsula. MGC has received honoraria, fees for advisory boards, and non-financial support from AstraZeneca, BI, Chiesi, GSK, Novartis, and Pfizer and grants from AstraZeneca, BI, Chiesi, and Pfizer. CR is director of Living With, which developed Living With COVID RecoveryTM and other digital health interventions used in healthcare systems including the NHS. RB is CEO of Perspectum, which developed CoverscanTM. AB has received research funding from NIHR, British Medical Association, Astra Zeneca, National Institute of Aging and European Union. AB is a Trustee of Long COVID SoS. All other authors report no competing interests.Clinical TrialISRCTN 10665760Funding StatementThis trial is part of a National Institute for Health Research-funded programme (NIHR: COV-LT2-0043). The CI is AB. Funding for the transport, storage, processing and biobanking of blood and MRI is supported by Perspectum Ltd (CI-AB). The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:South Central - Berkshire Research Ethics Committee (reference: 21/SC/0416) of the Health Research Authority UK gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol does not report results and no further data are available. Deidentified research data will be made publicly available when the study is completed and published.